Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.

A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.

Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.